HNF1A

Overview

HNF1A (hepatocyte nuclear factor 1 alpha) is a transcription factor of major biomedical importance, best known for its role in regulating gene expression in metabolic tissues and for its association with monogenic diabetes, particularly HNF1A-MODY (maturity-onset diabetes of the young). As a protein target, HNF1A is clinically relevant because variation in its function can alter pancreatic beta-cell and hepatic transcriptional programs, contributing to inherited dysglycemia and informing diagnostic classification of diabetes subtypes.

In the recent literature provided here, HNF1A appears primarily in the context of diabetes risk assessment rather than as a direct mechanistic focus in immunology. One study specifically addressed the development of a calculator for estimating the probability of HNF1A-MODY in Asian Indians using clinical and biochemical criteria. This underscores HNF1A’s continuing significance as a diagnostic and stratification marker in precision medicine for diabetes.

Focus of Latest Publications

Recent publications involving HNF1A have focused primarily on its clinical use in diabetes risk stratification rather than on direct mechanistic studies of the protein itself. In an Asian Indian cohort, investigators developed a calculator to estimate the probability of HNF1A-MODY, alongside HNF4A-MODY, using clinical and biochemical criteria. This work reflects ongoing efforts to improve recognition of monogenic diabetes in routine practice and to distinguish HNF1A-related disease from more common forms of diabetes.

Across the other recent studies provided, HNF1A was not the central experimental target. Instead, the literature emphasized transcriptional and epigenetic regulators of cell identity and immune function, including HNF4α, TCF1/TCF7, Mettl8, GSK-3, and proteostasis-related factors. These studies examined tumor cell plasticity, CD4 and CD8 T-cell differentiation, Treg-mediated immune evasion, and responses to immune checkpoint blockade, with therapeutic contexts including anti-PD-1, anti-CTLA-4, and kinase inhibition.

Taken together, the recent publication record suggests that HNF1A is currently appearing mainly in the context of MODY diagnosis and classification, while adjacent work in cancer and immunology is centered on related transcriptional networks rather than HNF1A directly. No new functional findings about HNF1A protein biology, signaling, or therapeutic targeting were reported in the abstracts provided.

Key Publications

NEWJul Cellular plasticity as a therapeutic vulnerability: HNF4α is a key target in lung adenocarcinoma. (The Journal of clinical investigation, 2026, PMID 42383354): "Dadzie et al. show that hepatocyte nuclear factor 4 α (HNF4α) promotes gastric identity in lung epithelial cells via a mechanism involving restriction of FOXA1 and FOXA2 transcription factors to gastric gene enhancer loci."
NEWJun Treg cells promote immunotherapy-induced immune evasion by restraining CD4 T cell control of MHC-I-deficient metastatic pancreatic cancer. (Science immunology, 2026, PMID 42361199): "Tumor-specific CD4 T cells adopted a TCF-1+SLAMF6+ progenitor state in lymph nodes and differentiated in tumors."
May GSK-3 regulates CD4-CD8 cooperation for super-armed CD8+ cytolytic T cells in immunotherapy against tumors. (Signal transduction and targeted therapy, 2026, PMID 42156357): "Here, we identify glycogen synthase kinase-3 (GSK-3) as a central regulator of TCF-1⁺ progenitor and memory CD8⁺ T-cell differentiation, where reduced GSK-3 expression enhances antiviral and anti-tumor immunity."
May Proteostasis sustains T cell differentiation potential and tumor-infiltrating lymphocyte function. (Cell, 2026, PMID 42061400): "Enforced expression of these ligases in T cells preserved stem-like TCF1+ populations and improved function in tumors and chronic infection."
Apr Ponatinib inhibits LCK and PI3K signaling and promotes CD8+ T stem cell memory cell development. (Nature communications, 2026, PMID 41946709): "ponatinib inhibits LCK and PI3K signaling to enhance the transcriptional functions of TCF7 and FOXO1, thereby promoting CD8+ TSCM cell differentiation."
Apr Targeting Mettl8-Tcf1 axis promotes CD8+ TPEX differentiation and antitumor immunity. (The Journal of experimental medicine, 2026, PMID 41891923): "Mechanistically, Mettl8 stabilizes Tcf7 mRNA via m3C modification and enhances Tcf1 protein expression."
May Development of a Calculator for HNF1A- and HNF4A-MODY in Asian Indians. (Journal of diabetes science and technology, 2026, PMID 41871534): "We aimed to develop a calculator to determine the probability of having HNF1A-MODY (hepatocyte nuclear factor 1 alpha-maturity-onset diabetes of the young) or HNF4A (hepatocyte nuclear factor 4 alpha)-MODY (the commonest forms of MODY) in Asian Indians using clinical and biochemical criteria."